Onderneming Alnylam Pharmaceuticals, Inc.
Aandelen
ALNY
US02043Q1076
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
149,4 USD | -1,20% | -0,71% | -21,95% |
Vakgebied
Aantal werknemers: 2 100
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Ribonucleic Acid Interference Therapeutics
100,0
%
| 1 037 | 100,0 % | 1 828 | 100,0 % | +76,23% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
69,8
%
| 616 | 59,4 % | 1 276 | 69,8 % | +107,21% |
Europe
21,8
%
| 315 | 30,4 % | 399 | 21,8 % | +26,83% |
Rest of the World
8,4
%
| 107 | 10,3 % | 153 | 8,4 % | +43,31% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 61 | 19-09-16 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 13-08-19 |
Piyush Sharma
CMP | Compliance Officer | - | 21-09-22 |
Chief Tech/Sci/R&D Officer | - | 01-08-17 | |
Kevin Fitzgerald
CTO | Chief Tech/Sci/R&D Officer | 56 | 01-01-05 |
James Bilotta
CTO | Chief Tech/Sci/R&D Officer | - | 01-10-15 |
Pushkal Garg
CTO | Chief Tech/Sci/R&D Officer | 56 | 29-10-14 |
Joshua Brodsky
IRO | Public Communications Contact | - | 01-02-21 |
Investor Relations Contact | 43 | 01-09-15 | |
Eric Green
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 18-12-15 |
Charles Sigal
BRD | Director/Board Member | 72 | 22-08-22 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 10-01-19 |
Amy Schulman
CHM | Chairman | 63 | 01-07-14 |
Phillip Sharp
FOU | Founder | 79 | 14-06-02 |
Peter Kellogg
BRD | Director/Board Member | 67 | 07-03-23 |
Michael Bonney
BRD | Director/Board Member | 65 | 17-12-14 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 23-04-12 |
Colleen Reitan
BRD | Director/Board Member | 64 | 01-06-18 |
Chief Executive Officer | 61 | 19-09-16 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 126 491 778 | 125 969 953 ( 99,59 %) | 0 | 99,59 % |
Bedrijfsgegevens
Alnylam Pharmaceuticals, Inc.
675 West Kendall Street Henri A. Termeer Square
02142, Cambridge
+617 551 8200
http://www.alnylam.comSector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-21,95% | 18,9 mld. | |
+33,63% | 50,93 mld. | |
-0,09% | 42,12 mld. | |
+49,62% | 42,05 mld. | |
-4,96% | 29,18 mld. | |
+11,18% | 26,02 mld. | |
+8,61% | 13,21 mld. | |
+24,73% | 12,17 mld. | |
+28,31% | 12,16 mld. | |
-6,26% | 11,42 mld. |
- Beurs
- Aandelen
- Koers ALNY
- Onderneming Alnylam Pharmaceuticals, Inc.